share_log

Bristol-Myers Discloses Prelim. $6.29 GAAP & Non-GAAP EPS Impact For 3 Months Ended March 31 Related To Acquired IPRD & Licensing Income

Bristol-Myers Discloses Prelim. $6.29 GAAP & Non-GAAP EPS Impact For 3 Months Ended March 31 Related To Acquired IPRD & Licensing Income

百時美披露了截至3月31日的3個月中與收購的IPRD和許可收入相關的6.29美元GAAP和非GAAP每股收益的初步影響
Benzinga ·  04/24 21:41

Bristol-Myers Discloses Prelim. $6.29 GAAP & Non-GAAP EPS Impact For 3 Months Ended March 31 Related To Acquired IPRD & Licensing Income

百時美披露了截至3月31日的3個月中與收購的IPRD和許可收入相關的6.29美元GAAP和非GAAP每股收益的初步影響

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論